Comparative Analysis of BPC-157 and TB-500

Two Different Molecules With a Shared Reputation

BPC-157 and TB-500 are two of the peptides lifters and athletes mention most often for injury recovery, and many people use them together. They aren't related molecules. BPC-157 is a 15-amino-acid chain based on a protein in gastric juice. TB-500 is a 7-amino-acid fragment of thymosin beta-4, a protein found in many human tissues. What they share is a research base made up almost entirely of animal and cell studies, plus a large community of users reporting their own results.

This page compares the two side by side. Four companion articles go deeper, and each is linked in the section it expands on.

What Each Peptide Is

BPC-157

BPC-157 (body protection compound 157) is a synthetic pentadecapeptide, meaning a peptide made of 15 amino acids. Its sequence comes from a protein in human gastric juice, so much of the early rodent work looked at the stomach and gut before moving on to musculoskeletal injuries. Based on animal data, a 2025 systematic review in HSS Journal reported a half-life of under 30 minutes, with breakdown in the liver and clearance through the kidneys.

TB-500

TB-500 is a product name, not a scientific one. In 2012, the anti-doping lab at Ghent University analyzed a product sold as TB-500 and identified Ac-LKKTETQ: an acetylated fragment made of residues 17-23 of thymosin beta-4 (Tβ4). Full Tβ4 is 43 amino acids long, so TB-500 is a much smaller molecule. Lab research has linked the 17-23 region of Tβ4 to angiogenesis (new blood vessel growth) and hair-follicle growth.

Vendor copy and forum posts often describe TB-500 as the full 43-amino-acid protein, and many users say they aren't sure which one their vials contain. The human trials of Tβ4 tested the full protein, so their results can't be assumed to apply to the fragment.

How They're Thought to Work

The proposed mechanisms differ. In rodent and cell studies, BPC-157 has been linked to higher growth hormone receptor expression and to lower levels of inflammatory signals such as TNF-α and IL-6. Lab studies of Tβ4 report increased VEGF (a growth factor that drives blood vessel formation) and dampened NF-κB inflammatory signaling. Most of that Tβ4 work used the full-length protein; far less has tested the fragment sold as TB-500.

None of these pathways has been measured in people taking either peptide. Our side-by-side look at how BPC-157 and TB-500 work covers the proposed mechanisms in more detail.

What the Evidence Shows

For BPC-157, the 2025 HSS Journal systematic review screened 544 articles and kept 36 studies. Thirty-five were preclinical and one was clinical, and the authors found no clinical safety data. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine counted three published human pilot studies: a retrospective series in which 14 of 16 people reported knee pain relief after injections of BPC-157 alone or combined with Tβ4, a bladder-instillation pilot in 12 people with interstitial cystitis, and an intravenous safety study in two adults. None had a control group. As of October 2026, a University of Arkansas randomized, placebo-controlled pilot in people recovering from rotator cuff surgery is listed on ClinicalTrials.gov as not yet recruiting, with a planned start in January 2027.

For TB-500, the gap is wider. As of October 2026, FDA's page on bulk substances with safety concerns says the agency has not identified any human exposure data for the Tβ4 fragment. Full Tβ4 has reached human trials, mainly as eye drops. A Phase 3 trial of 0.1% Tβ4 eye drops (SEER-2) in neurotrophic keratopathy had not posted results as of October 2026, and even a positive result would describe an eye drop of the full protein, not injected TB-500.

On this site's evidence scale, that puts BPC-157 at emerging (consistent animal data, a little early human data) and TB-500 at preliminary. For how these compare with peptides backed by larger trials, see what the clinical peptide data actually shows.

Injury Recovery: Animal Results vs. User Reports

Rodent studies of BPC-157 report better outcomes in tendon, ligament, muscle and bone injury models. The animal record for TB-500 mostly comes from full Tβ4, tested in models such as heart injury and skin wounds. No human trial has measured tissue healing with either peptide.

User reports are mixed. In forum threads, some people describe less pain and a faster return to training within a few weeks, while others notice no change after 3-6 weeks. Several things could explain the gap: rodent results may not carry over to people, gray-market vials vary in what they contain, expectation effects are strong with pain, and people who improve are more likely to post about it.

Many users inject near the injury. The animal studies mostly gave BPC-157 by intramuscular, intraperitoneal, intravenous or oral routes and still reported effects at the injury, and no human study has compared injection sites. Our article on BPC-157 and TB-500 for specific injuries goes through injury types one at a time.

Dosing as Reported

No human trial has established a dose for either peptide. The clearest published human dose figures for BPC-157 come from the intravenous pilot: 10 mg on the first day and 20 mg on the second, each infused over an hour, in two adults aged 58 and 68. No human dose has been tested for the TB-500 fragment.

Community and vendor figures are far smaller than those infusions:

• BPC-157: users commonly report 250-500 mcg per day by subcutaneous injection, sometimes split into two doses. Some describe 1-2 mg per day for injuries, with no dose-finding data behind it.
• TB-500: vendor guidance describes 2-2.5 mg twice weekly for 4-6 weeks, then monthly doses. Forum users describe 2-5 mg twice weekly, or 0.5-2 mg daily or every other day.

Stacking the two is common, and the pairing is often promoted as synergistic. The only human data on the combination is the uncontrolled knee series mentioned above. The dosing protocols article for this pair covers routes and timing as users and vendors describe them.

Safety Signals

The three BPC-157 pilots reported no adverse effects, but together they included about 30 people, which is too few to catch uncommon problems. In animals, the HSS Journal review found no acute lethal or toxic dose reported across a wide range of doses and routes, but no study had followed adverse events for more than 6 weeks. For the TB-500 fragment there are no human safety data at all. Full Tβ4 has been given to people in small trials, and again those results don't transfer directly.

Two concerns come up repeatedly in the literature and regulatory documents:

• Angiogenesis and tumors. Both peptides are studied partly because they promote blood vessel growth, and pathologic angiogenesis helps tumors grow. The 2025 narrative review describes this risk as theoretical for BPC-157 and notes preclinical work in which BPC-157 counteracted VEGF-driven tumor growth. No human data address it for either peptide.
• Impurities and immune reactions. FDA's review flagged possible immunogenicity for some injection routes and peptide-related impurities for both compounds. Vials sold as research peptides don't have to meet the sourcing and testing rules that apply to pharmacy compounding.

Users commonly mention injection-site irritation and, early on, fatigue or low mood, often when using both peptides together.

Legal and Sport Status

As of October 2026, neither peptide is FDA-approved as a medicine. On April 15, 2026, FDA announced that 12 peptides, including BPC-157 and the TB-500 fragment, would come off Category 2 of its 503A bulk substances list (substances with significant safety concerns) after their nominators withdrew the nominations. Leaving Category 2 lifted a do-not-compound posture but didn't authorize compounding.

At FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, FDA staff recommended against adding either peptide to the 503A bulks list. According to a LumaLex Law summary of the meeting, the committee voted 8-6-1 in favor of adding each one. That vote is advice, not law; adding a substance takes notice-and-comment rulemaking. As of October 2026, FDA hasn't published a proposed rule. Even if it does, listing would only let licensed pharmacies compound the peptides for individual prescriptions. It wouldn't change the status of vials sold as research chemicals.

For tested athletes, WADA's 2026 Prohibited List names BPC-157 under S0 (non-approved substances) and names TB-500 under S2.3, which covers "Thymosin-β4 and its derivatives e.g. TB-500". Both are banned in and out of competition. The legal status article for these two peptides covers other countries and drug testing.

What to Watch Next

• FDA's response to the July 2026 vote. A proposed rule would be the first formal step toward legal compounding of either peptide in the US.
• Controlled BPC-157 data. The University of Arkansas rotator cuff pilot is due to start in January 2027.
• SEER-2 results for Tβ4 eye drops. These will say something about the full protein in the eye, not about injected TB-500.
• What TB-500 vials contain. Independent testing that separates the 7-residue fragment from full Tβ4 would settle which molecule users are taking.